Trial Profile
A Single Dose Study to Assess Pharmacokinetics of SCH 54031 in Patients With Renal Impairment (P05655).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Hepatitis B; Hepatitis C; HIV infections; Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 27 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 31 Jul 2012 Planned end date changed from 1 Jul 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.